What they say: Introduction:
A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published in the 1 July 2014 issue of the journal “EMBO” by Prof Sinclair, North BJ, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product Lifespan extension therapy: Abelmoschus esculentus extract increases life span via up-regulation of its target gene BubR1.
From Research Findings to Therapeutic Opportunity:
This study suggests a natural product-based life extension therapy. Abelmoschus esculentus extract, by increasing the expression of its target gene, it may increase the expression of BuBR1. Thereby, it may: (1) delay diseases of aging; (2) slow down aging; and (3) prolong median life span. Thus, pharmacological formulations encompassing“Abelmoschus esculentus extract or an active compound isolated from it“ may be used to extend the lifespan of an individual.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, Natural product Lifespan extension therapy: Abelmoschus esculentus extract increases life span via up-regulation of its target gene BubR1, 7/November/2016, 8.11 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
Undisclosed information: How Abelmoschus esculentus extract increases the expression of BubR1 and extends mammalian life-span
# Research cooperation
Results guaranteed if not refunded